[1]. Scotto J, Fears TR, Fraumeni Jr(1996) “Solar Radiation. In: Schottenfeld D, Fraumeni JF Jr, eds: Cancer Epidemiology and Prevention. 2nd ed. New York, NY: Oxford University Press. PP 355-72.
[2]. Vogelstein B, Kinzler KW(2004).” Cancer Genes and the Pathways they Control. Nat Med 2004; Vol.10, No.8,pp. 789-99.
[3]. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL(1988).” Genetic Alterations during Colotectal- Tumor Development. N Engl J Med. No. 319, pp. 525-532.
[4]. Hanahan D, Weinberg RA(2000).” The Hallmarks of Cancer Cell. No. 100, pp. 57-70.
[5]. Hanahan D, Weinberg RA(2000).” The Hallmarks of Cancer Cell”. Vol.100,No.1, pp.57-70.
[6]. Sonnenschein C, Soto AM( 2008).” Theories of Carcinogenesis: an Emerging perspective. Semi Cancer Biol. Vol. 18No.5, pp. 372-7.
[7]. Pakin DM(2006).” The Global Health Burden of Infection-Associated Cancers in the years 2002. Int J Cancer. Vol.118, No.12, pp. 3030-44.
[8]. National RC. Committee to Assess Health Risks from Exposure to Low Levels of Inoizing Radiation(2011).” BEIR VII Phase 2. Washington.
[9]. Fazel R, Krumholz HM, Wang R, et al. (2009).” Exposure to Low-Dose Ionizing Radiation from Medical Imaging Procedures. N Engl J Med. 2009, Vol.361, No.9. 849-57.
[10]. William WN Jr, Heymach JV, Kim ES, et al (2009).” Molecular Targets for Cancer Chemoprevention. Nat Rev Drug Discov. Vol.8, No.3,pp. 213-25.
[11]. Seto M, Honma K, Nakagawa M. (2010). “Diversity of Genome Profiles in Malignant Lymphoma. Cancer Science.No.101, pp. 573-578.
[12]. Staal SP. Huebner K, Croce CM, Parsa N, et al(1988). “ The Akt-1 Proto Oncogene Maps to Human Chromosome 14, Band q32, a Site of Chromosome Rearrangement in some Hematopoietic Neoplasma. Journal of Genomics. No.2, pp. 96-98.
[13]. Park M, Testa JR, Blair DG, Parsa N, et al. ( 1988).” Two Rearranged Met Alleles on Chromosome 7 to other Markers Tightly Linked to Cystic Fibrosis. Proceeding of the National Academy of Sciences, USA. No.85pp. 2667-2671.
[14]. Offit K, Parsa N, Jhanwar SC, Filippa DA, et al.( 1992).” Denotes a Subset of Low to Intermediate Grade B-cell Non-Hodgkin΄s Lymphoma”. Journal of the American Society of Hematology(Blood). No. 80, pp.45-60.
[15]. Parsa N, Gaidano G, Mukherjee, AB, Hauptschein RS, et al.( 1994). “Cytogenetic and Molecular Analysis of 6q Deletions in Burkitt΄s Lymphoma Cell Lines”. Journal of Genes, Chromosomes & Cancer. No. 9, pp. 13-18.
[16]. Papanicolaou, GJ, Parsa N, Meltzer PS, Trent JM(1997). “Assignments of Interferon Gama Receptor(INFGR1) to Human Chromosome Bands” 6q24.1 →q24.2 by Fluorescent In Situ hybridization”. Journal of Cytogenetics and Cell Genetics. 1997; 76: 181-182.
[17]. Cigudosa JC, Parsa N, Louie DC, Filippa DA, Mitlema F, Chaganti RSK( 1999). Cytogenetic Analysis of 363 Consecutively Ascertained Diffuse Large B-cell Lymphomas. Journal of Genes, chromosoma & Cancer”. No. 25, pp.123-133.
[18]. Shtivelman E, Lifshitz B, Gale RP, Canaani E.(1985).” Fused Transcript of abl and bcr Genes in Chronic Myelogenous Leukemia. Nature No.315, pp.550-554.
[19].Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N Engl J Med 2001;344:1031-1037.
[20]. Joensuu H, Dimitrijevic S. Tyrosine Kinase Inhibitor Imatinib (STI571) As An Anticancer Agent for Solid Tumours. Ann Med 2001;33:451-455.
[21]. King CR, Kraus MH, Aaronson SA.(1985)” Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma”. Science ;229: 974-976.
[22]. Heinrich MC, Blanke CD, Druker BJ, Corless CL.(2002). Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies. J Clin Oncol 2002;20:1692-1703.
[23]. Wei, Qingyi; Lei Li, David Chen (2007). DNA Repair, Genetic Instability, and Cancer. World Scientific. ISBN 981-270-014-5.
[24]. Hogervorst FB. et al. (2003). “Large Genomic Deletions and Duplications in the BRCA1 Gene Identified by a Novel Quantitative Method”. Cancer Res. Vol.63 , No.7,pp. 1449–1453.
[25]. Friedenson B (2010). “A Theory that Explains the Tissue Specificity of BRCA1/2 Related and Other Hereditary Cancers”. Journal of Medicine and Medical Sciences Vol. 1, No.8, 372–384.
[26]. Tonin, PN; Serova, O; Lenoir, G; Lynch, H; Durocher, F; Simard, J; Morgan, K; Narod, S. (1995). “BRCA1 Mutations in Ashkenazi Jewish Women”. American Journal of Human Genetics Vol.57, No. 1,p. 189.
[27]. Narod, SA; Foulkes, WD. (2004). “BRCA1 and BRCA2: 1994 and Beyond”. Nature Reviews on Cancer Vol.4, No.9,pp. 665–676.
[28]. Fesik SW, Shi Y. (2001). “Controlling the Caspases”. Science Vol.294,pp. 1477–1478.
[29]. Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB (2000). “Bcl-2 Inhibits Bax Translocation from Cytosol to Mitochondria during Drug-Induced Apoptosis of Human Tumor Cells”. Cell Death Differ. Vol., No.1,pp. 102–111.
[30]. Santos A. Susin; Daugas, E; Ravagnan, L; Samejima, K; Zamzami, N; Loeffler, M; Costantini, P; Ferri, KF et al. (2000). “Two Distinct Pathways Leading to Nuclear Apoptosis”. Journal of Experimental Medicine Vol.192, No. 4, pp. 571–580.
[31]. Zhou, G. P. & Doctor, K. (2003). “Subcellular Location Prediction of Apoptosis Proteins. PROTEINS”: Structure, Function, and Genetics No.50, pp. 44-48.
[32]. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S. “Isolation and Characterization of a Human p53 cDNA Clone: Expression of the Human P53 Gene”. EMBO J. Vol.3, No13.pp. 3257–3262.
[33]. May, P. and May, E. (1999). “Twenty Years of p53 Research: Structural and Functional Aspects of the p53 Protein”. Oncogene, No.18, pp. 7621–7636.
[34]. McBride OW, Merry D, Givol D (1986). “The Gene for Human p53 Cellular Tumor Antigen is Located on Chromosome 17 Short Arm (17p13)”. Proc. Natl. Acad. Sci. U.S.A. 83 (1): 130–134.
[35]. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM (1986). “Localization of gene for human p53 tumour antigen to band 17p13”. Nature 320 (6057): 84–85.
[36]. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). “p53 mutations in human cancers”. Science 253 (5015): 49–53
[37]. Koshland DE (1993). “Molecule of the Year”. Science Vol.262 , No.5142, P. 1953.
[38]. Thomas RK, et al. High-throuphut oncogene mutation profiling in human cancer. Nature Genetics. 2007; 39: 347-351.
[39].Weinstein IB, Joe AK.(2006).” Mechanisms of Disease”, Oncogene Addiction-Arationale for Molecular Targeting in Cancer Therapy. Nature Clinical Practice Oncology.No. 3, pp.448-457.
[40]. Wei Q, Lei L, Chen D. DNA Repair, Genetic Instability and cancer. World scientific. 2007; 270-014.
[41].Thompson CB.( 1995).” Apoptosis in the Pathogenesis and Treatment of Disease. Science.; 267(5203): 1456-62. Doi: 10. 1126/Science. 7878464. PMID 7878464.
[42].NagataS.Apoptosis DNA fragmentation. Exp. Cell Res. 2000, Vol. 256No.1,pp. 12-8. Doi: 10.1006/ excr. 4834. PMID 10739646.
[43]. Baak JP, Path FR, Hermsen MA, Meijer G, et al.( 2003).” Genomics and Proteomics in Cancer. Eur J Cancer. No. 39,pp. 1199-1215.
[44]. Scarpa A, Moore PS, Rigaud G, Meenestrina F.(2001).” Genetic in Primary Mediastinal B-cell lymphoma” An Updata. Leukemia & Lymphoma No. 41pp. 47-53.
[45]. Tachdjian G, Aboura A, Lapierre JM, Viguei F.( 2002).” Cytogenetic Analysis from DNA by Comparative Genomic Hybridization. Ann Genet,No.43,pp.147-154.
[46]. Kashiwagi H, Uchida K.( 2003).” Genome- Wide Profiling of Gene Amplification and Deletion in Cancer. Human Cell. No. 13,pp. 135-141.
[47]. Pollak JR, Perou CM, Alizadeh AA, Eisen MB, et al.(2003).” Genome-Wide Analysis of DNA Copy- Number Changes Using Cdna Microarrays. Nature Genet. No.23pp. 41-46.
[48].Albertson DG, Pinkel D.(2003).” Genomic Microarrays in Human Genetic Disease and Cancer”. Hum Mol Genet.,pp. 145-52.